Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial

Rakesh Popat; Nicholas  Counsell; Ruth de Tute; Dunnya De‐Silva; Elizabeth H. Phillips; Jamie D. Cavenagh; Toyin Adedayo; Nivette Braganca; Claire Roddie; Matthew Streetly; Steve Schey; Mickey B. C. Koh; Josephine Crowe; Treen C. Morris; Gordon Cook; Paul Smith; Laura Clifton-Hadley; Neil Rabin; Roger G. Owen; Kwee Yong

doi:10.1111/bjh.17391

Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial

Rakesh Popat, Nicholas Counsell, Ruth de Tute, Dunnya De‐Silva, Elizabeth H. Phillips, Jamie D. Cavenagh, Toyin Adedayo, Nivette Braganca, Claire Roddie, Matthew Streetly, Steve Schey, Mickey B. C. Koh, Josephine Crowe, Treen C. Morris, Gordon Cook, Paul Smith, Laura Clifton-Hadley, Neil Rabin, Roger G. Owen, Kwee Yong

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e19-e22
Journal	British Journal of Haematology
Volume	193
Issue number	3
DOIs	https://doi.org/10.1111/bjh.17391
Publication status	Published - 14 May 2021

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

Access to Document

10.1111/bjh.17391

Cite this

Popat, R., Counsell, N., Tute, R. D., De‐Silva, D., Phillips, E. H., Cavenagh, J. D., Adedayo, T., Braganca, N., Roddie, C., Streetly, M., Schey, S., Koh, M. B. C., Crowe, J., Morris, T. C., Cook, G., Smith, P., Clifton-Hadley, L., Rabin, N., Owen, R. G., & Yong, K. (2021). Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial. British Journal of Haematology, 193(3), e19-e22. https://doi.org/10.1111/bjh.17391

@article{82da75743a0e41f18ce9372fe7e37714,

title = "Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial",

author = "Rakesh Popat and Nicholas Counsell and Tute, {Ruth de} and Dunnya De‐Silva and Phillips, {Elizabeth H.} and Cavenagh, {Jamie D.} and Toyin Adedayo and Nivette Braganca and Claire Roddie and Matthew Streetly and Steve Schey and Koh, {Mickey B. C.} and Josephine Crowe and Morris, {Treen C.} and Gordon Cook and Paul Smith and Laura Clifton-Hadley and Neil Rabin and Owen, {Roger G.} and Kwee Yong",

note = "Funding Information: RP: Janssen Honoraria and travel support for meetings outside the submitted work; RT: nothing to disclose; NC: grants from Blood Cancer UK, grants and other from Janssen, during the conduct of the study; DDS: nothing to disclose; EP: nothing to disclose; JC: Janssen Honoraria outside the submitted work; TA: grants from Blood Cancer UK, grants and other from Janssen, during the conduct of the study; NB: grants from Blood Cancer UK, grants and other from Janssen, during the conduct of the study; MS: Janssen Honoraria outside the submitted work; SS: nothing to disclose; MK: consultancy and honoraria from Gilead and Alexion; JC: nothing to disclose; MQ: nothing to disclose; TCM: nothing to disclose; SDS: Janssen Cilag Consultancy, Honoraria, education grant and research funding outside the submitted work; AV: nothing to disclose; GC: grants and personal fees from Janssen outside the submitted work; CC: nothing to disclose; GP: grants and personal fees from Janssen outside the submitted work; MC: grants and personal fees from Celgene, personal fees and non‐financial support from Takeda, personal fees and non‐financial support from Abbvie, personal fees and non‐financial support from Amgen, personal fees from Chugai, personal fees from Jazz Pharmaceuticals, personal fees and non‐financial support from Janssen UK, outside the submitted work; PS: grants from Blood Cancer UK, grants and other from Janssen, during the conduct of the study; LCH: grants from Blood Cancer UK, grants and other from Janssen, during the conduct of the study; NR: Janssen Consultancy, travel support for meetings and Speakers Bureau outside the submitted work; RO: Janssen Consultancy travel support outside the submitted work; KY: Janssen Honoraria and Research Funding. Funding Information: The authors acknowledge the research staff working across all sites, the patients and their carers. KY and RP are supported by the UCLH/ UCL NIHR Biomedical Research Centre. The trial was coordinated by the CRUK and UCL CTC. Blood Cancer UK conducted an independent review of the study proposal and provided funding. Janssen LLC provided bortezomib free of charge and contributed to trial management costs, but had no involvement in the design, conduct, analysis or interpretation. All authors had full access to the data and the corresponding author was responsible for manuscript submission. Funding Information: The authors acknowledge the research staff working across all sites, the patients and their carers. KY and RP are supported by the UCLH/ UCL NIHR Biomedical Research Centre. The trial was coordinated by the CRUK and UCL CTC. Blood Cancer UK conducted an independent review of the study proposal and provided funding. Janssen LLC provided bortezomib free of charge and contributed to trial management costs, but had no involvement in the design, conduct, analysis or interpretation. All authors had full access to the data and the corresponding author was responsible for manuscript submission.",

year = "2021",

month = may,

day = "14",

doi = "10.1111/bjh.17391",

language = "English",

volume = "193",

pages = "e19--e22",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley & Sons Ltd",

number = "3",

}

Popat, R, Counsell, N, Tute, RD, De‐Silva, D, Phillips, EH, Cavenagh, JD, Adedayo, T, Braganca, N, Roddie, C, Streetly, M, Schey, S, Koh, MBC, Crowe, J, Morris, TC, Cook, G, Smith, P, Clifton-Hadley, L, Rabin, N, Owen, RG & Yong, K 2021, 'Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial', British Journal of Haematology, vol. 193, no. 3, pp. e19-e22. https://doi.org/10.1111/bjh.17391

TY - JOUR

T1 - Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial

AU - Popat, Rakesh

AU - Counsell, Nicholas

AU - Tute, Ruth de

AU - De‐Silva, Dunnya

AU - Phillips, Elizabeth H.

AU - Cavenagh, Jamie D.

AU - Adedayo, Toyin

AU - Braganca, Nivette

AU - Roddie, Claire

AU - Streetly, Matthew

AU - Schey, Steve

AU - Koh, Mickey B. C.

AU - Crowe, Josephine

AU - Morris, Treen C.

AU - Cook, Gordon

AU - Smith, Paul

AU - Clifton-Hadley, Laura

AU - Rabin, Neil

AU - Owen, Roger G.

AU - Yong, Kwee

N1 - Funding Information: RP: Janssen Honoraria and travel support for meetings outside the submitted work; RT: nothing to disclose; NC: grants from Blood Cancer UK, grants and other from Janssen, during the conduct of the study; DDS: nothing to disclose; EP: nothing to disclose; JC: Janssen Honoraria outside the submitted work; TA: grants from Blood Cancer UK, grants and other from Janssen, during the conduct of the study; NB: grants from Blood Cancer UK, grants and other from Janssen, during the conduct of the study; MS: Janssen Honoraria outside the submitted work; SS: nothing to disclose; MK: consultancy and honoraria from Gilead and Alexion; JC: nothing to disclose; MQ: nothing to disclose; TCM: nothing to disclose; SDS: Janssen Cilag Consultancy, Honoraria, education grant and research funding outside the submitted work; AV: nothing to disclose; GC: grants and personal fees from Janssen outside the submitted work; CC: nothing to disclose; GP: grants and personal fees from Janssen outside the submitted work; MC: grants and personal fees from Celgene, personal fees and non‐financial support from Takeda, personal fees and non‐financial support from Abbvie, personal fees and non‐financial support from Amgen, personal fees from Chugai, personal fees from Jazz Pharmaceuticals, personal fees and non‐financial support from Janssen UK, outside the submitted work; PS: grants from Blood Cancer UK, grants and other from Janssen, during the conduct of the study; LCH: grants from Blood Cancer UK, grants and other from Janssen, during the conduct of the study; NR: Janssen Consultancy, travel support for meetings and Speakers Bureau outside the submitted work; RO: Janssen Consultancy travel support outside the submitted work; KY: Janssen Honoraria and Research Funding. Funding Information: The authors acknowledge the research staff working across all sites, the patients and their carers. KY and RP are supported by the UCLH/ UCL NIHR Biomedical Research Centre. The trial was coordinated by the CRUK and UCL CTC. Blood Cancer UK conducted an independent review of the study proposal and provided funding. Janssen LLC provided bortezomib free of charge and contributed to trial management costs, but had no involvement in the design, conduct, analysis or interpretation. All authors had full access to the data and the corresponding author was responsible for manuscript submission. Funding Information: The authors acknowledge the research staff working across all sites, the patients and their carers. KY and RP are supported by the UCLH/ UCL NIHR Biomedical Research Centre. The trial was coordinated by the CRUK and UCL CTC. Blood Cancer UK conducted an independent review of the study proposal and provided funding. Janssen LLC provided bortezomib free of charge and contributed to trial management costs, but had no involvement in the design, conduct, analysis or interpretation. All authors had full access to the data and the corresponding author was responsible for manuscript submission.

PY - 2021/5/14

Y1 - 2021/5/14

U2 - 10.1111/bjh.17391

DO - 10.1111/bjh.17391

M3 - Letter

SN - 0007-1048

VL - 193

SP - e19-e22

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -